维拉帕米二甲双胍联合用药对高血压合并Ⅱ型糖尿病患者降压及降糖作用临床观察

Objective To observe blood pressure lowering effect and the blood glucose lowering effect on the combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (diabetes mellitus, DM). Methods 129 cases of hypertension in patients with type 2 DM were divided into two groups, Verapamil treatment group, 98 cases in the control group 31 cases. (1) Verapamil treatment groups: Verapamil hydrochloride sustained-release capsules 180 mg/d, Metformin 750 ～ 1500 mg/d,Valsartan 80 ～ 160 mg/d, A Division horses Lin 100 mg/d, (2) control group, Valsartan 80 ～ 160 mg/d, Verapamil hydrochloride sustained-release capsules 180 mg/d, Aspirin 100 mg/d. (3) Blood pressure observation: Subjects in patients as early as 7: 00 and 22: 00 evening, measured two times a day and record systolic blood pressure blood pressure decreased significantly compared with those before treatment,4,6 weeks after the blood pressure weeks treatment their difference was significant (P<0.01), but the blood pressure has not dropped to normal ment review TC, TG, LDL decreased significantly after treatment, the difference was significant (P<0.05),HDL increased after treatment of (2.73±0.17), after treatment there was significant difference between improved (P<0.05), Verapamil treatment group was significantly better than the control group. Conclusion The combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (DM) patients has good blood pressure lowering effect and blood glucose lowering effect.     

维拉帕米二甲双胍联合用药对高血压合并Ⅱ型糖尿病患者降压及降糖作用临床观察

Objective To observe blood pressure lowering effect and the blood glucose lowering effect on the combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (diabetes mellitus, DM). Methods 129 cases of hypertension in patients with type 2 DM were divided into two groups, Verapamil treatment group, 98 cases in the control group 31 cases. (1) Verapamil treatment groups: Verapamil hydrochloride sustained-release capsules 180 mg/d, Metformin 750 ～ 1500 mg/d,Valsartan 80 ～ 160 mg/d, A Division horses Lin 100 mg/d, (2) control group, Valsartan 80 ～ 160 mg/d, Verapamil hydrochloride sustained-release capsules 180 mg/d, Aspirin 100 mg/d. (3) Blood pressure observation: Subjects in patients as early as 7: 00 and 22: 00 evening, measured two times a day and record systolic blood pressure blood pressure decreased significantly compared with those before treatment,4,6 weeks after the blood pressure weeks treatment their difference was significant (P<0.01), but the blood pressure has not dropped to normal ment review TC, TG, LDL decreased significantly after treatment, the difference was significant (P<0.05),HDL increased after treatment of (2.73±0.17), after treatment there was significant difference between improved (P<0.05), Verapamil treatment group was significantly better than the control group. Conclusion The combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (DM) patients has good blood pressure lowering effect and blood glucose lowering effect.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

心肌梗死合并糖尿病患者QT间期和QT离散度的改变及不同治疗方法对其的影响

Objective To compare the QTc and QTcd between type 2 diabetic and non-diabetic patients with post-myocardial infarction (post-MI) ,and to compare the QTcd in type 2 diabetic patients with post-MI treated with insulin,sulfonylurea,mefformin,or diet alone. Methods We measured the QTc and QTcd through simultaneous 12-lead Electrocardiogram in 138 post-MI patients,including 70 type 2 diabetic (of which,23 were assigned to re-ceive insulin,20 glipizide,16 mefformin,11 diet control) and 68 non-diabetic patients. Result Compared with post-MI patients without diabetes,those with type 2 diabetes had significantly higher QTc [(377.2±24.3) ms vs (342.9±27.5)ms,t=7.79,P<0.01] and QTcd [(48.8±19.7)ms vs (40.3±26.6)ms,t=2.14,P<0.05]. There were no significant difference between the mefformin group and the diet control group (P>0.05). The QTc and QTcd in the insulin group were significantly higher than those in the other three group s(P<0.05),and the QTc and QTcd in the glipizide group were higher than those in the mefformin group or diet control group(P<0.05,and P<0.01,respectively). Conclusion Type 2 diabetes is associated with an additional increase in the QTcd in post-MI patients,suggesting higher mortality risk in post-MI patients with type 2 diabetes. Insulin and glipizide may in-crease the QTc and QTcd in post-MI patients with diabetes. These effects were more significant in the insulin therapy group.     

2型糖尿病合并胆石症与胰岛素抵抗相互关系的探讨

目的:探讨2型糖尿病合并胆石症与胰岛素抵抗之间关系.方法:测定35例2型糖尿病合并胆石症患者的空腹血糖、空腹胰岛素、三酰甘油,总胆固醇,高密度脂蛋白,低密度脂蛋白(LDL),并计算胰岛素敏感指数,观察其变化及相互关系,并与42例不伴胆石症的2型糖尿病患者相比较.结果:2型糖尿病并胆石症组与不伴胆石症组相比较,前者空腹胰岛素、三酰甘油、总胆固醇,低密度脂蛋白明显升高,胰岛素敏感指数明显下降.结论:胰岛素抵抗可能是2型糖尿病患者胆石形成的危险因素.     

2型糖尿病合并微量蛋白尿与胰岛素抵抗关系的临床研究

目的:探讨2型糖尿病合并微量蛋白尿与胰岛素抵抗的关系.方法:对40例2型糖尿病合并微量蛋白尿患者与44例未合并微量蛋白尿的糖尿病患者的空腹血糖(FBG),胰岛素(FINS),胰岛素敏感性指数(ISI)和血脂等进行比较分析,并与所有患者微量白蛋白进行相关分析,结果:2型糖尿病合并微量蛋白尿的ISI显著低于未合并微量蛋白尿组.结论:2型糖尿病合并微量蛋白尿时存在明显胰岛素抵抗.     

二甲双胍对胰岛素抵抗患者血脂和胰岛素敏感性的影响

目的：研究二甲双胍对2型糖尿病合并高血压病患血脂和胰岛素敏感性的影响。方法：将76例2型糖尿病合并高血压病患分为31例治疗组与45例对照组，并与26例2型糖尿病组相比。三组应用格列齐特或格列吡嗪降糖，治疗组加用二甲双胍0．5g,3次／d，治疗组与对照组用卡托普利或依那普利降压。治疗2个月后胰岛素及C肽兴奋试验，测胰岛素、C肽浓度、空腹血糖、血脂，计计算胰岛素敏感指数、C肽与胰岛素面积。治疗前后测体重指数。结果：对照组的胰岛素、C肽浓度及面积与2型糖尿病组相比，上升非常显，胰岛素敏感指数降低25．17％；治疗组的C肽及胰岛素面积上升显，胰岛素敏感指数降低11．31％，总胆固醇、载脂蛋白B降低，高密度脂蛋白胆固醇、载脂蛋白A1上升，治疗组治疗后体重指数下降显。结论：二甲双胍能改善2型糖尿病合并高血压病患的血脂代谢，提高胰岛素敏感性。     

2型糖尿病患者血清抵抗素水平的变化研究

目的探讨人血清抵抗素水平与2型糖尿病的关系.方法 2型糖尿病患者48例和正常对照组47例,采用酶联免疫分析法检测空腹血清抵抗素、胰岛素水平;同时测血糖、血压、血脂、身高、体重,计算腰围、臀围、体重指数、腰臀比值和胰岛素敏感指数、胰岛素抵抗性、胰岛B细胞功能.结果 2型糖尿病组的体重指数、甘油三酯、血清抵抗素水平显著高于正常对照组（P＜0.05）;相关分析显示血清抵抗素水平与体重指数、腰围、空腹胰岛素、血压呈正相关.在正常对照组,血清抵抗素水平与胰岛素敏感指数、胰岛素抵抗性、胰岛B细胞功能相关.而且血清抵抗素水平在糖尿病肥胖组显著高于糖尿病非肥胖组和正常对照组（P＜0.05）.结论 2型糖尿病患者血清抵抗素水平升高,与肥胖相关,血清抵抗素可能是联系肥胖和2型糖尿病的重要因素.     

2型糖尿病TNF—α与IR的关系

目的:探讨2型糖尿病血清肿瘤坏死因子与胰岛素抵抗之间的关系。方法:用氧化酶法,放免法和酶联免疫法分别测定正常健康人23例,2型糖尿病28例的空腹血糖、空腹胰岛素(Fins)、血清TNF-α。计算胰岛素敏感指数(ISI)。结果:2型糖尿病TNF-α水平较正常对照组升高(P<0.01),而ISI较正常组降低(P<0.01)。结论:2型糖尿病TNF-α水平增高与胰岛素抵抗有关,可能参与2型糖尿病的发生和发展。     

肝源性糖尿病及其胰岛素抵抗临床观察

目的 观察肝炎后肝硬化继发糖尿病患者糖代谢紊乱和胰岛素抵抗相关指标。方法 30例既往有肝硬化病文(Child-pugh A、B级)但无糖尿病史，血压正常的肝56性糖尿病患者(组1)，分别检测空腹血糖(FPG)、空腹血浆硬岛素(FPI)、空腹C—肽，糖化血红蛋白(HbAlc)，计算胰岛素敏感性指数(ISI)，并以非糖尿病忠者30例(组2)和26例正常人(组3)为对照研究。结果 与组2组3比较，组1空腹血糖升高(分别为P＜0．05和P＜0．01)，空腹C—肽水平无明显差异，但空腹血浆胰岛素水平升高(P均＜0．05)，胰岛素敏感性指数降低(分别为P＜0．05和P＜0．01)。组2与组3间比较，组2空腹血浆硬岛素水平轻度升高，硬岛素敏感性指数降低，但差异无统计学意义。结论 硬岛素抵抗和高硬岛素血症可能为肝源性糖尿病形成的危险因索。     

脑梗死合并高血压与糖尿病时胰岛素抵抗的临床观察

目的　观察老年人脑梗死合并高血压、糖尿病时胰岛素抵抗 (IR)的情况。方法　 4 1例单纯脑梗死患者 (组 1) ,2 1例脑梗死合并高血压患者 (组 2 )、19例脑梗死合并糖尿病患者 (组 3)及 2 6例正常对照组 ,分别测定收缩压 (SBP)、舒张压 (DBP)、空腹血糖 (FBG)、空腹胰岛素 (FINS)、C肽、总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDL C)、高密度脂蛋白胆固醇 (HDL C)、载脂蛋白 (Apo)A1及ApoB。 结果　 3组患者的SBP、DBP、FBG、FINS、TG、ApoB均明显高于对照组 ,胰岛素敏感性指数则明显下降(P <0 .0 5或P <0 .0 1)。组 1、组 2的C肽显著高于对照组 ,组 2、组 3的TC及LDL C显著高于对照组 ,而HDL C、ApoA1仅在组 3与对照组比较差异明显 (P <0 .0 5 )。组 2与组 1比较 ,SBP、DBP、FINS及C肽有所升高 ,但仅SBP、DBP有统计学意义。组 3与组 1比较 ,TG、TC、LDL C差异显著。结论　老年脑梗死患者存在明显的IR ;合并高血压或糖尿病时 ,IR、代谢紊乱更为严重。     

胰岛素抵抗危险因素的探讨

目的　研究 2型糖尿病胰岛素抵抗的危险因素及其内在变化关系。方法　对 83例初诊 2型糖尿病患者 [正常体质量组 34例 ,超重和 (或 )肥胖组 4 9例 ]胰岛素抵抗的 8种危险因素 ,包括空腹血糖、空腹胰岛素、三酰甘油、胆固醇、高密度脂蛋白胆固醇、收缩压、舒张压和体质量指数 ,进行了测定 ,并与 32例正常对照组比较。结果　 2型糖尿病组空腹血糖、空腹胰岛素、三酰甘油、血压较对照组高 (P <0 .0 1～ 0 .0 5 ) ,高密度脂蛋白胆固醇较对照组低 ;2型糖尿病正常体质量组与超重和 (或 )肥胖组间血糖、血脂、血压比较差异无统计学意义 ,但超重和 (或 )肥胖组空腹胰岛素水平高于正常体质量组 (P <0 .0 1)。结论　 2型糖尿病一旦诊断 ,多存在一定程度的胰岛素抵抗 ,这种抵抗与体质量增加、三酰甘油升高有关 ,且易形成高血压 ,直接影响糖尿病多种慢性并发症及其预后     

2型糖尿病胰岛素抵抗与缺血性脑卒中关系的初步探讨

目的　探讨胰岛素抵抗对 2型糖尿病缺血性脑卒中的可能发病机制。方法　将 194例 2型糖尿病患者分为缺血性脑卒中组 6 3例 ,无脑卒中组 131例 ,两组患者进行血压、血糖、血脂、糖化血红蛋白 (HbA1c)、胰岛素 (INS)及胰岛素敏感性 (ISI)等差异性比较。结果　两组间ISI、HbA1c、总胆固醇 (TC)差异有统计学意义 (P <0 .0 1) ,体重指数 (BMI)、空腹胰岛素 (FINS)、空腹血糖 (FBG) /FINS和高密度脂蛋白 胆固醇 (HDL C)差异亦有统计学意义 (P <0 .0 5 ) ;两组间糖耐量试验各时相血糖值比较差异均无统计学意义 (P >0 .0 5 ) ,而脑卒中组各时相INS均较无脑卒中组明显升高 (P <0 .0 5或 P <0 .0 1) ,尚可见两组INS峰值后移。结论　 2型糖尿病除了糖脂代谢紊乱外 ,胰岛素抵抗和代偿性高胰岛素血症可能是缺血性脑卒中的又一危险因素     

二甲双胍对2型糖尿病合并冠状动脉病变的影响

目的研究二甲双胍对糖尿病合并冠状动脉病变的影响。方法 253例糖尿病合并冠心病患者按照随机数字表法分为二甲双胍组(500 mg,3次/天)及吡格列酮组(15 mg,1次/天),疗程12个月。观察血管内皮功能、胰岛B细胞功能、冠状动脉造影的变化。结果与治疗前相比,治疗12个月后两组患者的血糖、胰岛抵抗指数均显著下降,空腹及餐后胰岛素水平、胰岛B细胞功能均显著升高,差异有统计学意义(均P0.05)。治疗12个月后两组间的血糖、胰岛素抵抗指数、胰岛素水平、胰岛B细胞功能比较,差异均无统计学意义(均P0.05);但治疗12个月后二甲双胍组的体质量指数低于吡格列酮组,差异有统计学意义(P0.05)。与治疗前相比,治疗12个月后二甲双胍组的冠状动脉三支病变及弥漫性血管病变发生率较治疗前显著降低,差异有统计学意义(P0.05),二甲双胍组的冠状动脉三支病变及弥漫性血管病变发生率较吡格列酮组显著降低,差异有统计学意义(P0.05)。结论二甲双胍与吡格列酮对2型糖尿病患者均具有明显的降糖、改善胰岛功能、降低胰岛素抵抗的作用。在降低体质量指数及改善糖尿病合并冠状动脉病变方面,二甲双胍优于吡格列酮组。